key: cord-0795496-dvunyiuu
authors: Dagotto, Gabriel; Yu, Jingyou; Barouch, Dan H.
title: Approaches and Challenges in SARS-CoV-2 Vaccine Development
date: 2020-08-10
journal: Cell Host Microbe
DOI: 10.1016/j.chom.2020.08.002
sha: c6032136b4b3a1c6863f45013d94d94447a10a0c
doc_id: 795496
cord_uid: dvunyiuu

Abstract The explosive spread of SARS-CoV-2 suggests that a vaccine will be required to end this global pandemic. Progress in SARS-CoV-2 vaccine development to date has been faster than for any other pathogen in history. Multiple SARS-CoV-2 vaccine candidates have been evaluated in preclinical models and are currently in clinical trials. In this Perspective, we discuss three topics that are critical for SARS-CoV-2 vaccine development: antigen selection and engineering, preclinical challenge studies in non human primate models, and immune correlates of protection.

SARS-CoV-2 was initially identified as the etiologic agent responsible for a cluster of severe pneumonia cases in Wuhan, China in December 2019 (Chan et al., 2020; Huang et al., 2020; Li et al., 2020; Wu et al., 2020; Zhu et al., 2020c) . On March 11 th , 2020, the World Health Organization (WHO) declared SARS-CoV-2 a global pandemic, and the disease was named COVID-19. In response to this pandemic, industry, government, philanthropy, non-governmental organizations, and academia are collaborating to develop therapeutic and prophylactic countermeasures, including vaccines. SARS-CoV-2 is a member of the Coronaviridae family, joining severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) as coronaviruses causing severe disease in humans. These pathogens are single-stranded, positive-sense RNA viruses and encode four structural proteins, spike (S), envelope (E), membrane (M), and nucleocapsid (N), as well as multiple non-structural proteins (Srinivasan et al., 2020) . Similar to SARS-CoV, the SARS-CoV-2 S protein binds angiotensin-converting enzyme 2 (ACE2) as its primary host receptor to mediate viral entry (Hoffmann et al., 2020) , and S is the main target for neutralizing antibodies.

J o u r n a l P r e -p r o o f SARS-CoV-2 has proven to be highly transmissible, including from asymptomatic and presymptomatic individuals (Arons et al., 2020; McMichael et al., 2020) . Currently, at least six vaccine candidates have been tested in nonhuman primates and have reported either partial or complete protection Gao et al., 2020; Mercado et al., 2020; van Doremalen et al., 2020; Wang et al., 2020; Yu et al., 2020) . Moreover, multiple promising vaccine candidates have entered clinical trials, and early phase clinical trial data has also been reported (Folegatti et al., 2020; Jackson et al., 2020; Mulligan et al., 2020; Zhu et al., 2020a) . In this Perspective, we focus on three core issues related to SARS-CoV-2 vaccine development: antigen selection and engineering, preclinical challenge studies, and immune correlates of protection. A discussion of clinical development and deployment strategies for SARS-CoV-2 vaccines, while also important, is beyond the scope of this manuscript.

Coronaviruses encode multiple structural and non-structural proteins that could potentially serve as immunogens for a SARS-CoV-2 vaccine. The best characterized proteins are spike (S), nucleocapsid (N), membrane (M), and envelope (E). S has most commonly been utilized in coronavirus vaccine studies, due to its pivotal role in mediating viral entry into cells (Song et al., 2019) . Mature S is a trimeric class I fusion protein located on the surface of the virion. Many coronaviruses proteolytically process S into the S1 and S2 domains. The S1 fragment contains the receptor binding domain (RBD) and the S2 fragment contains the fusion peptide, which are responsible for receptor binding and cell fusion, respectively. For SARS-CoV, S has been demonstrated to be the primary target of neutralizing antibodies.

In mouse models of SARS-CoV, passive transfer and vaccine studies have shown that S-specific antibodies confer protective immunity (Enjuanes et al., 2008; Yang et al., 2004) . For SARS-CoV-2, studies with monoclonal antibodies have shown that SARS-CoV-2 infected humans develop robust neutralizing antibody responses against S, and in particular the receptor binding domain (RBD) Hansen et al., 2020; Ju et al., 2020; Rogers et al., 2020; Shi et al., 2020; Zost et al., 2020) .

In addition to S, early studies with SARS-CoV suggested that most infected individuals developed an antibody response to N (Pei et al., 2005) . N protein immunized BALB/c mice also induced CD4 + and CD8 + T-cells (Liu et al., 2006) . However, vaccination with vaccines expressing N resulted in no protection against SARS-CoV challenge as well as enhanced infection, which was characterized by increased pulmonary eosinophil infiltration (Deming et al., 2006) . Passive transfer of anti-N antibodies did not generate an enhanced response, leading the authors to believe that the increased severity was linked to a T-cell response (Deming et al., 2006) . Similarly, BALB/c mice vaccinated with a vaccinia virus (VV) expressing S, M, N, and E showed enhanced viral infection upon SARS-CoV challenge, which was associated with a T h 2 response with pulmonary infiltration of neutrophils, eosinophils, and lymphocytes (Yasui et al., 2008) .

The M and E proteins have garnered less interest as vaccine targets due to lower immunogenicity (Du et al., 2008a) , although SARS-CoV patient sera has been shown to be reactive to M peptides (Wang et al., 2003) . Of the less studied proteins, Orf3a has been shown to be capable of raising a neutralizing polyclonal antibody response in rabbits (Akerström et al., 2006) .

Currently, most vaccines for SARS-CoV-2 are focused on S (Folegatti et al., 2020; Jackson et al., 2020; Mulligan et al., 2020; Zhu et al., 2020a; Zhu et al., 2020b) . To target the SARS-CoV-2 S protein in its native prefusion form, antigen stabilization strategies have been used (Figure 1) . For MERS-CoV and SARS-CoV, introduction of two prolines (PP) in the S2 subunit effectively stabilized the S in its prefusion conformation (Pallesen et al., 2017) . The prefusion stabilized MERS-CoV S generated higher neutralizing antibody titers when compared to native S trimer (Pallesen et al., 2017) . This mutation prevented conformational changes of S in the presence of its receptor, ACE2, or trypsin (Kirchdoerfer et al., 2018) . This stabilization method has also been demonstrated to stabilize the SARS-CoV-2 S (Wrapp et al., 2020) and has been applied to multiple SARS-CoV-2 vaccine candidates Jackson et al., 2020; Mercado et al., 2020) . Unlike SARS-CoV, but similar to MERS-CoV, SARS-CoV-2 includes a furin cleavage site between the S1 and S2 domains. For MERS-CoV, researchers mutated the J o u r n a l P r e -p r o o f furin cleavage site to enhance homogeneity and stability (Walls et al., 2019) . Some investigators have also added a foldon trimerization tag to the C-terminus (Walls et al., 2020) , and deletion of the cytoplasmic tail of the SARS-CoV S has been shown to increase neutralizing antibody titers (Yang et al., 2004) . Current vaccine candidates in clinical trials are also exploring the inclusion of a tissue plasminogen activator leader sequence (tPA) with S (Folegatti et al., 2020; Mercado et al., 2020; Zhu et al., 2020a) . The tPA leader can increase immunogen secretion and elicit increased humoral immune responses in influenza (Luo et al., 2008) and HIV vaccines (Wallace et al., 2013) , although cellular immunogenicity was only increased in the influenza vaccine.

The receptor binding domain (RBD) alone has also been explored as an immunogen. In preclinical studies in mice, rabbits, and monkeys, vaccination with modified vaccinia Ankara (MVA) expressing the full-length SARS-CoV S induced neutralizing antibodies that targeted RBD (Chen et al., 2005) . Moreover, depletion of RBD-specific antibodies significantly reduced convalescent plasma neutralizing capabilities , consistent with the concept that RBD is the primary target of Sspecific neutralizing antibodies. When rabbits were immunized with a variety of SARS-CoV-2 S immunogens, including RBD, S1, S2, and modified variants, RBD was found to elicit five-fold higher affinity antibodies than the other immunogens (Ravichandran et al., 2020) . Sprague-Dawley rats immunized with SARS-CoV-2 RBD also elicited a strong neutralizing antibody response (Quinlan et al., 2020) . RBD immunogens have been combined with a foldon trimerization tag in the BNT162b1 COVID-19 RNA vaccine candidate (Mulligan et al., 2020) .

We recently compared a series of SARS-CoV-2 S immunogens in the context of both DNA vaccines and Ad26 vectors Yu et al., 2020) . DNA vaccines encoding the fulllength S elicited higher neutralizing antibody titers compared with DNA vaccines encoding several S deletion mutants and also afforded improved protection against SARS-CoV-2 challenge in rhesus macaques . Ad26 vectors were also generated encoding a series of S variants, and the J o u r n a l P r e -p r o o f full-length S with the PP stabilizing mutations proved the most immunogenic and afforded the best protection against SARS-CoV-2 challenge in rhesus macaques .

An optimal model for SARS-CoV-2 infection studies would involve an animal species permissive to viral replication and that develops pathologic and clinical features consistent with the human disease.

Clinical manifestations of COVID-19 in humans are usually mild but can include cough, fever, pneumonia, and occasionally respiratory failure and death . Non-human primates (NHPs) have significant genetic homology to humans and are often useful models for infectious diseases, although cost and availability can be limiting. In both rhesus and cynomolgus macaques , virus shedding could be detected in nasal, throat, and rectal swabs and in bronchoalveolar lavage for approximately 2 weeks after infection with SARS-CoV-2 using either intratracheal and intranasal infection or intratracheal, intranasal, ocular, and oral infection Munster et al., 2020; Rockx et al., 2020) . Early data suggests the utility of both macaque species as animal models for SARS-CoV-2 infection, although respiratory disease has been reported to be mild. The potential utility of African green monkeys as a model is also being explored. We recently demonstrated that SARS-CoV-2 infected macaques were also robustly protected against re-challenge, demonstrating natural protective immunity .

At least six SARS-CoV-2 vaccine challenge studies in macaques have been published at the time of this writing Gao et al., 2020; Mercado et al., 2020; van Doremalen et al., 2020; Wang et al., 2020; Yu et al., 2020) (Table 1) . These vaccine studies in NHPs have included inactivated vaccines [PiCoVacc (Gao et al., 2020) , BBIBP-CorV ], DNA vaccines , RNA vaccines (mRNA-1273 ), and adenovirus based vaccines [ChAdOx1 , Ad26 ]. PiCoVacc and BBIBP-CorV are based on J o u r n a l P r e -p r o o f SARS-CoV-2 CN2 and SARS-CoV-2 HB02 strains, respectively. The viruses were grown in Vero cells and inactivated using ß-propiolactone and were evaluated as two-or three-shot immunization regimens (Gao et al., 2020; Wang et al., 2020) . The DNA and mRNA-1273 vaccines encoded stabilized S immunogens and were tested as two-shot immunization regimens .

The ChAdOx1 vaccine expressed a codon-optimized full-length S with a human tissue-type plasminogen activator precursor (tPA) leader sequence and was tested as a single-shot and a two-shot vaccine regimen . The optimal Ad26 vaccine expressed a prefusion stabilized S immunogen and was tested as a single-shot vaccine .

Following vaccination, macaques were challenged by SARS-CoV-2 by the intratracheal, intranasal, oral, and/or ocular routes. Efficacy was determined in these studies by assessment of viral loads in the upper and lower respiratory tracts. Most studies are now focusing on analysis of subgenomic RNA rather than genomic RNA (Wölfel et al., 2020) , since subgenomic RNA is believed to be more reflective of replicating virus, rather than input challenge virus. The inactivated vaccine PiCoVacc resulted in reduced viral loads in throat swabs (Gao et al., 2020) . The inactivated vaccine BBIBP-CorV also decreased viral loads in throat swabs . The DNA vaccine encoding the full-length S resulted in >3.1 and >3.7 log 10 reductions in median subgenomic RNA levels in BAL and nasal swabs, respectively . The mRNA-1273 vaccine resulted in undetectable subgenomic RNA in lungs in all but one macaque, and more rapid clearance of virus from nasal swabs .

The optimal Ad26-S.PP vaccine resulted in undetectable subgenomic RNA in lungs and only one breakthrough in nasal swabs . The ChAdOx1 vaccine resulted in reduced subgenomic RNA in BAL but no decrease in nasal swabs .

The different challenge doses, strains, routes, and assays utilized make direct comparisons among these studies difficult. Nevertheless, these studies provide a substantial amount of preclinical data demonstrating protective efficacy of multiple vaccine candidates in nonhuman primates. These data help inform the ongoing clinical development programs for these vaccines. A limitation of all these studies is J o u r n a l P r e -p r o o f that macaques do not develop severe disease, respiratory failure, or death. Small animal models are currently being developed that may model severe disease, including hamsters and transgenic mice.

Determining immune correlates of protection (CoP) for SARS-CoV-2 will be critical for guiding vaccine development. Currently, mechanistic CoP for SARS-CoV-2 have not yet been fully determined, although several studies point to the importance of both humoral immunity.

Neutralizing antibodies (nAb) represent a commonly studied immune correlate of protection.

Early human challenge studies reported that volunteers with higher pre-existing anti-CoV 229E neutralizing antibody titers (>5) demonstrated lower proportions of virus isolation and upper respiratory infection than those with low neutralizing titers (≤5) (Bradburne et al., 1967) . Pre-challenge serum antibody titers were also negatively associated with upper respiratory infections, nasal virus shedding, and disease severity (Barrow et al., 1990; Callow, 1985) . Passive administration of convalescent sera, purified IgG or monoclonal antibodies have also been shown to suppress SARS-CoV challenge/infection and associated disease progression in mice, hamsters, ferrets and humans Roberts et al., 2006; Subbarao et al., 2004; Sui et al., 2005; Yuan et al., 2015) .

For SARS-CoV-2, neutralizing monoclonal antibodies isolated from convalescent COVID-19 patients have been shown to inhibit SARS-CoV-2 infection in both prophylactic and therapeutic settings in rhesus monkeys and hamsters (Rogers et al., 2020; Shi et al., 2020; Zost et al., 2020) . We also reported that DNA vaccines and Ad26 based vaccines induced neutralizing antibodies that strongly correlated with a reduction of viral loads in rhesus macaques Yu et al., 2020) . SARS-CoV-2 inactivated virus vaccines and mRNA vaccines also induced neutralizing antibodies and conferred protection in macaques Gao et al., 2020; Wang et al., 2020) . Collectively, these J o u r n a l P r e -p r o o f studies suggest that neutralizing antibody titers may serve as a useful biomarker for evaluating SARS-CoV-2 vaccines in both preclinical and clinical studies, although these correlates need to be confirmed in humans.

A question that has been raised is whether sub-neutralizing levels of antibodies could have detrimental effects. A prior study revealed that a vaccinia vector-based vaccine expressing feline coronavirus S induced low titers of neutralizing antibodies, which led to early cat mortality upon challenge (Vennema et al., 1990) . Consistent with this observation, several studies observed enhanced respiratory disease (ERD) in response to SARS vaccines when antibodies had suboptimal potency or low binding affinity (Jaume et al., 2011; Wan et al., 2020; Wang et al., 2014) . A major effort in the field will therefore be the development of animal models for ERD for SARS-CoV-2.

In addition to neutralization, emerging evidence suggests that certain antibody Fc-mediated functioning may also contribute to protective efficacy , including antibody-dependent complement deposition (ADCD), antibody-dependent cellular phagocytosis (ADCP), and antibodydependent NK cell activation (ADNKA) (Zohar and Alter, 2020) . Mucosal immunity is also likely important for protection, since coronavirus infection occurs in the respiratory tract and potentially in the gastrointestinal tract (Xiao et al., 2020) . Pulmonary IgA was observed to be inversely associated with MERS-CoV infectivity in humans (Muth et al., 2015) , and animal studies have highlighted the potential role of mucosal immunity in defending SARS-CoV infection (Du et al., 2008b; Huang et al., 2009) .

Given that intranasal administration may induce stronger mucosal immunity in the respiratory tract than parenteral routes, it may prove useful to evaluate intranasal routes for vaccines (Roper and Rehm, 2009 ).

Cellular immunity also appears important in the control of coronavirus infections. Current evidence suggests that not all patients develop protective humoral immune responses, and asymptomatic patients or individuals with mild disease typically develop robust T cell responses (Mathew et al., 2020;  J o u r n a l P r e -p r o o f Sekine et al., 2020) . In a mouse model, SARS-CoV specific CD8 + T cell numbers correlated with virus clearance and increased survival (Zhao et al., 2010) . In addition, memory CD4 + T cells were associated with protective immunity against MERS-CoV (Zhao et al., 2016) . Recent studies have reported that neutralizing antibody titers correlated with SARS-CoV-2-specific T cell responses , and that IgG and IgA antibody titers correlated with S-specific CD4 + T cell responses (Grifoni et al., 2020) , suggesting that T cells may indirectly modulate the virus infection by orchestrating antibody production.

However, in DNA vaccine studies in mice and NHPs, T cell responses did not correlate with protection (Yang et al., 2004; Yu et al., 2020) . Nevertheless, severe patients tend to have a higher frequency of polyfunctional CD4 cells expressing IFNγ, IL-2 and TNF-α (Sekine et al., 2020; Thieme et al., 2020) , although it is possible that these high frequency T cells may simply represent long-term viral exposure (Altmann and Boyton, 2020) .

There is limited data on innate immune correlates of protection. Existing pathogenesis studies suggest that the excessive production of proinflammatory cytokines and chemokines (cytokine storm) is associated with poor clinical outcome (Channappanavar and Perlman, 2017) . Type I and type III interferons (IFN-I and IFN-III) have shown to be able to suppress SARS-CoV-2 infection in vitro (Sallard et al., 2020; Stanifer et al., 2020) and may represent innate immune responses that assist in controlling SARS-CoV-2 infection. Blocking IFN-I signaling in mice has been shown to increase viral load and mortality for SARS-CoV and MERS-CoV (Channappanavar et al., 2019; Frieman et al., 2010) .

Retrospective cohort studies have also suggested that induction of IFNs correlated with disease severity and viral load in both SARS and MERS patients (Cameron et al., 2007; Kim et al., 2016) . It is possible that early induction promotes viral clearance, whereas delayed IFN responses can cause viral persistence, inflammation and immunopathology (Park and Iwasaki, 2020) .

The potential off-target effects of BCG, historically used as a vaccine for tuberculosis, and other live attenuated organisms are also being explored for SARS-CoV-2 (Curtis et al., 2020) . Trained J o u r n a l P r e -p r o o f immunity is regarded as immunological memory in the innate immune system and likely mediated by epigenetic modifications (Netea et al., 2016) . If non-specific trained innate immunity protects against SARS-CoV-2, this would provide an intriguing alternate to antigen-specific vaccination.

A vaccine will likely be required to end the global SARS-CoV-2 pandemic (Lurie et al., 2020) . A successful vaccine will need to be safe, effective, durable, and deployable to large populations. There are currently at least 40 SARS-CoV-2 vaccine clinical trials ongoing, including the Moderna mRNA vaccine (Jackson et al., 2020) , the Pfizer mRNA vaccine (Mulligan et al., 2020) , the CanSino Ad5 based vaccine (Zhu et al., 2020a; Zhu et al., 2020b) , the AstraZeneca/Oxford ChAdOx1 based vaccine (Folegatti et al., 2020) , and the J&J Ad26 based vaccine. Most vaccine strategies aim to generate S-specific neutralizing antibodies, and preclinical studies have shown substantial protection against SARS-CoV-2 challenge in NHPs. Over the next several months, additional preclinical efficacy studies as well as studies on enhanced respiratory disease will likely be reported, and multiple large-scale clinical efficacy trials will be conducted. J o u r n a l P r e -p r o o f

Amino acids 15-28 in the ectodomain of SARS coronavirus 3a protein induces neutralizing antibodies

SARS-CoV-2 T cell immunity: Specificity, function, durability, and role in protection

Presymptomatic SARS-CoV-2 Infections and Transmission in a Skilled Nursing Facility

The effect of intranasal nedocromil sodium on viral upper respiratory tract infections in human volunteers

Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies

Effects of a "new" human respiratory virus in volunteers

Effect of specific humoral immunity and some non-specific factors on resistance of volunteers to respiratory coronavirus infection

Interferon-mediated immunopathological events are associated with atypical innate and adaptive immune responses in patients with severe acute respiratory syndrome

A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster

SARS-CoV-2 infection protects against rechallenge in rhesus macaques

IFN-I response timing relative to virus replication determines MERS coronavirus infection outcomes

Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology

Recombinant Modified Vaccinia Virus Ankara Expressing the Spike Glycoprotein of Severe Acute

Respiratory Syndrome Coronavirus Induces Protective Neutralizing Antibodies Primarily Targeting the Receptor Binding Region

Use of convalescent plasma therapy in SARS patients in Hong Kong. European journal of clinical microbiology & infectious diseases : official publication of the

Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates

Considering BCG vaccination to reduce the impact of COVID-19

Vaccine efficacy in senescent mice challenged with recombinant SARS-CoV bearing epidemic and zoonotic spike variants

Development of subunit vaccines against severe acute respiratory syndrome

Intranasal Vaccination of Recombinant Adeno-Associated Virus Encoding Receptor-Binding Domain of Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) Spike Protein Induces Strong Mucosal Immune Responses and Provides Long-Term Protection against SARS-CoV Infection

Vaccines to prevent severe acute respiratory syndrome coronavirus-induced disease

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind

SARS-CoV pathogenesis is regulated by a STAT1 dependent but a type I, II and III interferon receptor independent mechanism

Development of an inactivated vaccine candidate for SARS-CoV-2

Targets of T Cell Responses to SARS-CoV

Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals

Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail

Identification of a critical neutralization determinant of severe acute respiratory syndrome (SARS)-associated coronavirus: importance for designing SARS vaccines

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

A novel replication-competent vaccinia vector MVTT is superior to MVA for inducing high levels of neutralizing antibody via mucosal vaccination

An mRNA Vaccine against SARS-CoV-2 -Preliminary Report

Anti-severe acute respiratory syndrome coronavirus spike antibodies trigger infection of human immune cells via a pH-and cysteine protease-independent FcgammaR pathway

Human neutralizing antibodies elicited by SARS-CoV-2 infection

Clinical Progression and Cytokine Profiles of Middle East Respiratory Syndrome Coronavirus Infection

Stabilized coronavirus spikes are resistant to conformational changes induced by receptor recognition or proteolysis

Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia

Immunological characterizations of the nucleocapsid protein based SARS vaccine candidates

Immunization with plasmid DNA encoding influenza A virus nucleoprotein fused to a tissue plasminogen activator signal sequence elicits J o u r n a l P r e -p r o o f strong immune responses and protection against H5N1 challenge in mice

Developing Covid-19 Vaccines at Pandemic Speed

Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications. Science

Epidemiology of Covid-19 in a Long-Term Care Facility

Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques

Phase 1/2 Study to Describe the Safety and Immunogenicity of a COVID-19 RNA Vaccine Candidate (BNT162b1) in Adults 18 to 55 Years of Age: Interim Report. medRxiv

Respiratory disease and virus shedding in rhesus macaques inoculated with SARS-CoV-2. bioRxiv

Infectious Middle East Respiratory Syndrome Coronavirus Excretion and Serotype Variability Based on Live Virus Isolates from Patients in Saudi Arabia

Trained immunity: A program of innate immune memory in health and disease

Detection of SARS-CoV-2-Specific Humoral and Cellular Immunity in COVID-19 Convalescent Individuals

Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen

Type I and Type III Interferons -Induction, Signaling, Evasion, and Application to Combat COVID-19

Expression of SARS-coronavirus nucleocapsid protein in Escherichia coli and Lactococcus lactis for serodiagnosis and mucosal vaccination

The SARS-CoV-2 receptor-binding domain elicits a potent neutralizing response without antibody-dependent enhancement. bioRxiv

Antibody signature induced by SARS-CoV-2 spike protein immunogens in rabbits

Therapy with a Severe Acute Respiratory Syndrome-Associated Coronavirus-Neutralizing Human Monoclonal Antibody Reduces Disease Severity and Viral Burden in Golden Syrian Hamsters

Comparative pathogenesis of COVID-19, MERS, and SARS in a nonhuman primate model

Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model

SARS vaccines: where are we? Expert review of vaccines

Type 1 interferons as a potential treatment against COVID-19

Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19. bioRxiv : the preprint server for biology

A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2

From SARS to MERS, thrusting coronaviruses into the spotlight

Structural Genomics of SARS-CoV-2 Indicates Evolutionary Conserved Functional Regions of Viral Proteins

Critical Role of Type III Interferon in Controlling SARS-CoV-2 Infection in Human Intestinal Epithelial Cells

Prior infection and passive transfer of neutralizing antibody prevent replication of severe acute respiratory syndrome coronavirus in the respiratory tract of mice

Evaluation of Human Monoclonal Antibody 80R for Immunoprophylaxis of Severe Acute Respiratory Syndrome by an Animal Study, Epitope Mapping, and Analysis of Spike Variants

The SARS-CoV-2 T-cell immunity is directed against the spike, membrane, and nucleocapsid protein and associated with COVID 19 severity. medRxiv

ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques

Early death after feline infectious peritonitis virus challenge due to recombinant vaccinia virus immunization

Post-translational intracellular trafficking determines the type of immune response elicited by DNA vaccines expressing Gag antigen of Human Immunodeficiency Virus Type 1 (HIV-1)

Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein

Unexpected Receptor Functional Mimicry Elucidates Activation of Coronavirus Fusion

Molecular Mechanism for Antibody-Dependent Enhancement of Coronavirus Entry

Development of an Inactivated Vaccine Candidate

Assessment of immunoreactive synthetic peptides from the structural proteins of severe acute respiratory syndrome coronavirus

Antibody-dependent SARS coronavirus infection is mediated by antibodies against spike proteins

Virological assessment of hospitalized patients with COVID-2019

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

A new coronavirus associated with human respiratory disease in China

Evidence for Gastrointestinal Infection of SARS-CoV-2

Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. The Lancet Respiratory Medicine

A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice

Prior Immunization with Severe Acute Respiratory Syndrome (SARS)-Associated Coronavirus (SARS-CoV) Nucleocapsid Protein Causes Severe Pneumonia in Mice Infected with SARS-CoV

DNA vaccine protection against SARS-CoV-2 in rhesus macaques

IL-9 antibody injection suppresses the inflammation in colitis mice

Airway Memory CD4(+) T Cells Mediate Protective Immunity against Emerging Respiratory Coronaviruses

T cell responses are required for protection from clinical disease and for virus clearance in severe acute respiratory syndrome coronavirus-infected mice

Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind

Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised

A Novel Coronavirus from Patients with Pneumonia in China

Dissecting antibody-mediated protection against SARS-CoV-2

Potently neutralizing and protective human antibodies against SARS-CoV-2. Nature

A vaccine will likely be required to end the SARS-CoV-2 pandemic. In this Perspective, Dagotto, Yu and Barouch summarize the ongoing preclinical studies on SARS-Cov2 vaccine candidates and discuss standards for antigen selection and immune correlates of protection

We acknowledge support from the Ragon Institute of MGH, MIT, and Harvard, Mark 

Correspondence and requests for materials should be addressed to D.H.B.